FDA Approved Weight Loss Pill Might Not Be Your Best "Alli"
When taken on a low fat diet, the pill prevents the body from absorbing fat. But in talking to the experts NewsChannel 11 learned if you continue to eat a high fat diet while on Alli, you could pay an uncomfortable price.
Read the rest of this entry ... (325 words left)
2007/6/26
Accidents may happen with new over-the-counter diet drug
Glaxosmithkline has a tip for people who decide to try Alli, the over-the-counter weight-loss drug it is launching with a multimillion-dollar advertising blitz - keep an extra pair of pants handy.
Read the rest of this entry ... (549 words left)
2007/6/12
1st OTC diet pill with OK from FDA in stores Friday Diet pill with FDA backing due in stores this Friday
2007/6/6
Glaxo promising no miracles with new OTC weight drug alli
You won't lose weight in your sleep or shed pounds while eating anything you want - that's the sobering message from the maker of a weight loss pill poised to hit shelves next month.
Read the rest of this entry ... (273 words left)
2007/6/4
Hooked on to diet pills?
Stop right now! These are no miracle pills, and they definitely don’t provide a long term solution
Read the rest of this entry ... (373 words left)
2007/6/2
Alli Bringing A New Revolution
Weight Loss is one of the important issue is being discussed in
Read the rest of this entry ... (263 words left)
2007/5/30
British Experts: Diet Drug Orlistat (Xenical / alli) Better Choice Than Acomplia
Claims that diet drug rimonabant (Acomplia / Zimulti) offers benefits beyond those associated with weight loss may not be justified, according to a new report by independent British medical experts.
The diet drug has been sold as Acomplia in the U.K. since June 2006 for treatment of obese and some overweight adults, and developer Sanofi Aventis has claimed some of the improvement in cardiometabolic risk factors observed in clinical trials cannot solely be attributed to weight loss.
Cardiometabolic risk factors -- including low HDL (good) cholesterol, high LDL (bad) cholesterol, elevated fat levels in the blood, high blood pressure and insulin resistance -- in combination increase a person's chance of developing heart disease and/or type 2 diabetes.
Acomplia "has a beneficial effect on blood glucose and lipid levels -- a more beneficial effect than would be expected from weight loss alone," Sanofi claims on its website.
But experts writing in the Drug and Therapeutics Bulletin (DTB), published by the British Medical Journal (BMJ) on May 30th, said there was no proof in the clinical trials that Acomplia had any beneficial effects outside those expected by weight loss.
"It
might be related to increased activity based on the lifestyle advice
given to participants at the start of the trials," according to their
report. "Furthermore, it is not known whether rimonabant's effects on
individual risk factors translate into a reduced long-term likelihood
of cardiovascular events."
The experts said
the trials also showed rimonabant to have no effect on LDL cholesterol
and little or no effect on high blood pressure.
While the drug is available in the U.K., the country's National Institute for Health and Clinical Excellence (Nice) is still weighing whether and under what conditions the drug should be paid for by the National Health Service.
"Rimonabant has not been directly compared with other, less expensive, drug treatments for obesity. Also, as with these other treatments, it is not known whether rimonabant reduces the likelihood of obesity-related diseases, such as cardiovascular problems," the researchers concluded.
They said Xenical (orlistat) "is the drug for obesity for which there is the most evidence for efficacy and safety to date, and we have previously concluded that it is a reasonable option for obese patients where diet and exercise and/or behavioural measures alone have failed.
"On current evidence, we do not believe that rimonabant represents a significant advance for patients with obesity," they said.
Source: http://www.dietdrugreport.com/News/news-053007.htm
2007/5/29
Diet pill not magic
Read the rest of this entry ... (93 words left)
2007/5/25
EU regulators back Glaxo's OTC obesity treatment
The European Medicines Agency said on Friday its experts had recommended granting marketing authorisation for Glaxo's low-dose version of orlistat -- the active ingredient in Xenical -- based on the safety and efficacy of Roche's original product.
Glaxo's non-prescription drug was approved in February in the United States, where it is being launched under the brand name Alli.Source: http://investing.reuters.co.uk/
2007/5/24
Alli: Eagerly awaiting diet pills
Alli diet pill is presently under its pre-launch test. This weight loss medication works by obstructing the fat absorption into the body. Consumption of this diet drug thereby is effective in giving liberal opportunity to the already stored in fat to generate the required energy, assisting in trimming down of excessive fat. This is in turn consequential ineffective weight loss . Health experts are concerned about the potential abuse of the Alli drug once the diet pill becomes more readily available. There is particular concern over its use in children as well as adults who do not need tolose weight in order to maintain a healthy body . We call Alli is the form of “Lifestyle Diet Products" because Alli is designed to work easily with your busy lifestyle to give you maximum benefit and weight loss. Alli diet pills are regulated by the Food and Drug Administration agency (FDA), theirside effects are monitored and they may be advertised and prescribed for weight loss under certain condition and in certain pill-dosages.
Read the rest of this entry ... (42 words left)